Please login to the form below

Not currently logged in
Email:
Password:

ICER

This page shows the latest ICER news and features for those working in and with pharma, biotech and healthcare.

Novartis makes case for gene therapy Zolgensma in SMA

Novartis makes case for gene therapy Zolgensma in SMA

Novartis has already suggested that the one-time treatment could be priced around $4m per patient, but recently an independent US medicines pricing watchdog ICER urged Novartis for a fair pricing ... ICER says this price should be slashed by at least

Latest news

  • Biogen’s Spinraza overpriced, says ICER Biogen’s Spinraza overpriced, says ICER

    Expensive rare disease drugs like Biogen’s spinal muscular atrophy (SMA) therapy are “threatening the affordability and sustainability of the US health system”, says ICER. ... ICER has urged Novartis and Avexis for a fair pricing strategy, one that

  • FDA approves Novartis' next-gen MS drug Mayzent FDA approves Novartis' next-gen MS drug Mayzent

    Mayzent will be priced slightly higher than Ocrevus at $88, 000 per year, but according to an ICER report the cost per additional QALY for the drug would exceed usual thresholds

  • Gene Genie Gene Genie

    I was reminded of just such a puzzle recently when reading about how NICE, ICER and CADTH (their Canadian cousin) are cooperating on a project called ‘Valuing a Cure’.

  • NICE and Canadian counterpart to offer joint advice service NICE and Canadian counterpart to offer joint advice service

    Just last month NICE, CADTH and The US-based Institute for Clinical and Economic Review (ICER) announced they will team up on a medicines cost evaluation project.

  • How to pay for very high cost, curative drugs? ICER and NICE put their heads together How to pay for very high cost, curative drugs? ICER and NICE put their heads together

    The US-based Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence and the Canadian Agency for Drugs and Technologies in Health (CADTH) are ... ICER's Steven Pearson. “Patients and those who

More from news
Approximately 4 fully matching, plus 57 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics